The treatment of patients with vesicoureteral reflux

A clinical trial to compare the effectiveness of peripheral blood mononuclear cell (PBMC) with platelet rich plasma in vesicoureteral reflux patients before and after treatment

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190117042391N1

Enrollment

Registered

2019-02-15

Start date

2019-02-20

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vesicoureteral reflux. Vesicoureteral-reflux-associated uropathy

Interventions

Intervention group: this group will receive 5 cc peripheral blood mononuclear cell with platelet rich plasma that has been taken from each patient him/her-self and has been prepared..

Eligibility

Sex/Gender

All

Age

No minimum to 14 Years

Inclusion criteria

Inclusion criteria: Age less than 14 years old Grade 1 to 4 of vesicoureteral reflux Having indication for surgical intervention such as repeated pyelonephritis or the creation of new scars in the renal nuclear scan

Exclusion criteria

Exclusion criteria: Urinary tract infection Reflux grade 5 Secondary vesicoureteral reflux History of anti-reflux surgery

Design outcomes

Primary

Measure	Time frame
The status and grade of reflux. Timepoint: Before and 3 months after intervention. Method of measurement: Cystography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmin Mirsani

Mashhad University of Medical Sciences

Mirsania941@mums.ac.ir+98 51 3854 3031

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026